Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.3931
+0.0025 (0.64%)
At close: Jul 24, 2026, 4:00 PM EDT
0.4183
+0.0252 (6.41%)
After-hours: Jul 24, 2026, 7:46 PM EDT

Vivos Therapeutics Stock Forecast

VVOS's stock price has decreased by -92.99% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 3 analysts polled by S&P Global, Vivos Therapeutics stock has a consensus rating of "Buy" and an average price target of $2.12. The average 1-year stock price forecast is 439.30% higher than the current stock price, while the lowest is $0.75 (+90.79%) and the highest is $3.10 (+688.60%).

Price Target: $2.12 (+439.30%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$0.75$2.12$2.50$3.10
Change+90.79%+439.30%+535.97%+688.60%

Analyst Ratings

The average analyst rating for Vivos Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26Apr '26May '26Jun '26Jul '26
Strong Buy222222
Buy000000
Hold111111
Sell000000
Strong Sell000000
Total333333

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Alliance Global Partners
Alliance Global Partners
Hold
Maintains
$1.75$0.75
HoldMaintains$1.75$0.75+90.79%Jul 8, 2026
Ascendiant
Ascendiant
Buy
Reiterates
$3$3.1
BuyReiterates$3$3.1+688.60%Jun 4, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$2.5
BuyReiterates$2.5+535.97%Apr 17, 2026

Financial Forecast

Revenue This Year
24.06M
from 17.44M
Increased by 37.91%
Revenue Next Year
34.09M
from 24.06M
Increased by 41.71%
EPS This Year
-1.39
from -2.07
EPS Next Year
-0.79
from -1.39
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
16.89M16.02M13.80M15.03M17.44M24.06M
Revenue Growth
29.23%-5.10%-13.87%8.91%16.05%37.91%
Gross Profit
12.60M10.02M8.27M9.02M10.54M14.59M
Gross Margin
74.65%62.52%59.93%60.00%60.44%60.63%
Operating Income
-19.47M-25.03M-17.30M-11.17M-19.89M-20.71M
Net Income
-20.29M-23.85M-13.58M-11.14M-21.17M-23.82M
EPS
-----2.07-1.39
No. Analysts
-----3
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue20262027
High25.9M
Avg24.1M
Low22.1M

Revenue Growth

Revenue Growth20262027
High
48.6%
Avg
37.9%
Low
26.7%

EPS Forecast

EPS20262027
High-0.75
Avg-1.39
Low-2.14

EPS Growth

EPS Growth20262027
High-
Avg-
Low-